Previously, COP reduced MDA-MB-231 adhesion, migration, and invasion in vitro by downregulating MMP-9 and increasing TIMP-1, presumably due to its anti-metastatic effect on BC (Li et al., 2014). The gene discussed is MMP9; the disease is breast cancer.